Cargando…

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension

Inhaled iloprost efficiently improves pulmonary hemodynamics, exercise capacity, and quality of life in patients with pulmonary arterial hypertension (PAH). However, the process of inhalation is laborious for patients suffering from resting dyspnea. We describe a 75-year-old man with idiopathic PAH...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Kazuhiko, Emoto, Noriaki, Tamada, Naoki, Okano, Mitsumasa, Shinkura, Yuto, Yanaka, Kenichi, Onishi, Hiroyuki, Hiraishi, Mana, Yamada, Shinichiro, Tanaka, Hidekazu, Shinke, Toshiro, Hirata, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024293/
https://www.ncbi.nlm.nih.gov/pubmed/29781778
http://dx.doi.org/10.1177/2045894018781537
_version_ 1783336031497486336
author Nakayama, Kazuhiko
Emoto, Noriaki
Tamada, Naoki
Okano, Mitsumasa
Shinkura, Yuto
Yanaka, Kenichi
Onishi, Hiroyuki
Hiraishi, Mana
Yamada, Shinichiro
Tanaka, Hidekazu
Shinke, Toshiro
Hirata, Ken-ichi
author_facet Nakayama, Kazuhiko
Emoto, Noriaki
Tamada, Naoki
Okano, Mitsumasa
Shinkura, Yuto
Yanaka, Kenichi
Onishi, Hiroyuki
Hiraishi, Mana
Yamada, Shinichiro
Tanaka, Hidekazu
Shinke, Toshiro
Hirata, Ken-ichi
author_sort Nakayama, Kazuhiko
collection PubMed
description Inhaled iloprost efficiently improves pulmonary hemodynamics, exercise capacity, and quality of life in patients with pulmonary arterial hypertension (PAH). However, the process of inhalation is laborious for patients suffering from resting dyspnea. We describe a 75-year-old man with idiopathic PAH and a low gas transfer. Investigations excluded significant parenchymal lung disease and airflow obstruction (presuming FEV1/FVC ration > 70%). The patient struggled to complete iloprost inhalation due to severe dyspnea and hypoxemia. As such, we optimized the methods of oxygen supply from the nasal cannula to the trans-inhalator during the inhalation. We successfully shortened the inhalation duration that effectively reduced the laborious efforts required of patients. We also recorded pulmonary hemodynamics during inhalation of nebulized iloprost. This revealed significant hemodynamic improvement immediately following inhalation but hemodynamics returned to baseline within 2 hours. We hope that this optimization will enable patients with severe PAH to undergo iloprost inhalation.
format Online
Article
Text
id pubmed-6024293
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60242932018-07-05 The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension Nakayama, Kazuhiko Emoto, Noriaki Tamada, Naoki Okano, Mitsumasa Shinkura, Yuto Yanaka, Kenichi Onishi, Hiroyuki Hiraishi, Mana Yamada, Shinichiro Tanaka, Hidekazu Shinke, Toshiro Hirata, Ken-ichi Pulm Circ Case Report Inhaled iloprost efficiently improves pulmonary hemodynamics, exercise capacity, and quality of life in patients with pulmonary arterial hypertension (PAH). However, the process of inhalation is laborious for patients suffering from resting dyspnea. We describe a 75-year-old man with idiopathic PAH and a low gas transfer. Investigations excluded significant parenchymal lung disease and airflow obstruction (presuming FEV1/FVC ration > 70%). The patient struggled to complete iloprost inhalation due to severe dyspnea and hypoxemia. As such, we optimized the methods of oxygen supply from the nasal cannula to the trans-inhalator during the inhalation. We successfully shortened the inhalation duration that effectively reduced the laborious efforts required of patients. We also recorded pulmonary hemodynamics during inhalation of nebulized iloprost. This revealed significant hemodynamic improvement immediately following inhalation but hemodynamics returned to baseline within 2 hours. We hope that this optimization will enable patients with severe PAH to undergo iloprost inhalation. SAGE Publications 2018-06-13 /pmc/articles/PMC6024293/ /pubmed/29781778 http://dx.doi.org/10.1177/2045894018781537 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Nakayama, Kazuhiko
Emoto, Noriaki
Tamada, Naoki
Okano, Mitsumasa
Shinkura, Yuto
Yanaka, Kenichi
Onishi, Hiroyuki
Hiraishi, Mana
Yamada, Shinichiro
Tanaka, Hidekazu
Shinke, Toshiro
Hirata, Ken-ichi
The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title_full The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title_fullStr The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title_full_unstemmed The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title_short The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
title_sort optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024293/
https://www.ncbi.nlm.nih.gov/pubmed/29781778
http://dx.doi.org/10.1177/2045894018781537
work_keys_str_mv AT nakayamakazuhiko theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT emotonoriaki theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT tamadanaoki theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT okanomitsumasa theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT shinkurayuto theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT yanakakenichi theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT onishihiroyuki theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT hiraishimana theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT yamadashinichiro theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT tanakahidekazu theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT shinketoshiro theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT hiratakenichi theoptimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT nakayamakazuhiko optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT emotonoriaki optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT tamadanaoki optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT okanomitsumasa optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT shinkurayuto optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT yanakakenichi optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT onishihiroyuki optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT hiraishimana optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT yamadashinichiro optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT tanakahidekazu optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT shinketoshiro optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension
AT hiratakenichi optimizationofiloprostinhalationundermoderateflowofoxygentherapyinseverepulmonaryarterialhypertension